Significance of Clinicopathological Analyze with Major Pathologic Response in Initially Unresectable Hepatocellular Carcinoma after Combination Therapy: a Retrospective Cohort Study

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200065311

Enrollment

Unknown

Registered

2022-11-01

Start date

2022-10-30

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

achieved major pathological response or not:None

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: The initially unresectable hepatocellular carcinoma patientsunderwent salvage surgery after PD-1 inhibitors plus TKIs therapy in a tertiary hospital from March 2019 to October 2021.

Exclusion criteria

Exclusion criteria: Non-radical surgery or tumor pathological specimens were not evaluable.

Design outcomes

Primary

Measure	Time frame
The Ratio of Viable Tumor Cells;The recurrence-free survival;	—

Secondary

Measure	Time frame
The overall survival;	—

Countries

China

Contacts

Public ContactShichun Lu

Faculty of Hepato-Pancreato-Biliary Surgery, Chinese PLA General Hospital

lusc_301@163.com+86 13381210573

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026